Zobrazeno 1 - 10 of 66 pro vyhledávání: '"Famitinib"'
1
Akademický článek
Long-lasting complete response to SHR-1701 plus famitinib in refractory advanced gallbladder cancer: A case report
Autor: Lixia Yi, Xiaoyan Zhu, Jing Xie, Zhiqiang Meng
Publikováno v: Human Vaccines & Immunotherapeutics, Vol 19, Iss 3 (2023)
ABSTRACTBiliary tract cancer (BTC) is an aggressive malignancy with few options for advanced-stage treatment. The combination of PD-1/PD-L1 inhibitors with famitinib, a receptor tyrosine kinase (RTK) inhibitor, has demonstrated improved clinical outc
Externí odkaz: https://doaj.org/article/474a86c6039745eba38f411723991dd5
Zobrazit plný text záznamu
2
Akademický článek
Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 studyResearch in context
Autor: Xi Ding, Yi-Jun Hua, Xiong Zou, Xiao-Zhong Chen, Xi-Mei Zhang, Bei Xu, Yan-Feng Ouyang, Zi-Wei Tu, Hui-Feng Li, Chong-Yang Duan, Wei-Jing Zhang, Rui You, You-Ping Liu, Yong-Long Liu, Qi Yang, Pei-Yu Huang, Shu-Ni Wang, Jia Fan, Ming-Yuan Chen
Publikováno v: EClinicalMedicine, Vol 61, Iss , Pp 102043- (2023)
Summary: Background: Treatment options for patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) are not clear after progression on previous treatment with PD-(L)1 inhibitor; critical gaps in evidence remain for such cases. Immunothera
Externí odkaz: https://doaj.org/article/3354f790c5364e4ea88154d8ea5f0184
Zobrazit plný text záznamu
3
Akademický článek
Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma
Autor: Shuwen Yang, Dongmei Ji, Fen Xue, Tongzhen Chen, Yu Wang, Qinhai Ji
Publikováno v: Cancer Reports, Vol 6, Iss 1, Pp n/a-n/a (2023)
Abstract Background Anaplastic thyroid cancer (ATC) is considered the most lethal thyroid cancer, with an overall 5‐year survival rate below 10%. The FDA approved a BRAF/MEK inhibitor combination for the treatment of patients with BRAF‐mutated AT
Externí odkaz: https://doaj.org/article/37869252e6ec40a18b3020aea3469d8a
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Third‐generation EGFR inhibitor HS‐10296 in combination with famitinib, a multi‐targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR‐mutant non‐small cell lung cancer cells
Autor: Mi Zhang, Haitian Quan, Li Fu, Yun Li, Haoyu Fu, Liguang Lou
Publikováno v: Thoracic Cancer, Vol 12, Iss 8, Pp 1210-1218 (2021)
Abstract Background As a highly heterogeneous disease, lung cancer has a multitude of cellular components and patterns of gene expression which are not dependent on a single mutation or signaling pathway. Thus, using combined drugs to treat lung canc
Externí odkaz: https://doaj.org/article/55267ec3411d49fbbf76ee812de82b63
Zobrazit plný text záznamu
6
Akademický článek
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
Autor: Qiuyan Chen, Linquan Tang, Na Liu, Feng Han, Ling Guo, Shanshan Guo, Jianwei Wang, Huai Liu, Yanfang Ye, Lu Zhang, Liting Liu, Pan Wang, Yingqin Li, Qingmei He, Xiaoqun Yang, Qingnan Tang, Yang Li, YuJing Liang, XueSong Sun, Chuanmiao Xie, Yunxian Mo, Ying Guo, Rui Sun, Haoyuan Mo, Kajia Cao, Xiang Guo, Musheng Zeng, Haiqiang Mai, Jun Ma
Publikováno v: Cancer Communications, Vol 38, Iss 1, Pp 1-13 (2018)
Abstract Background Famitinib is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Previous studies have de
Externí odkaz: https://doaj.org/article/46a7ad2fd04d4b9cb6f325b208958fab
Zobrazit plný text záznamu
7
Akademický článek
Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
Autor: Rui-Hua Xu, Lin Shen, Ke-Ming Wang, Gang Wu, Chun-Mei Shi, Ke-Feng Ding, Li-Zhu Lin, Jin-Wan Wang, Jian-Ping Xiong, Chang-Ping Wu, Jin Li, Yun-Peng Liu, Dong Wang, Yi Ba, Jue-Ping Feng, Yu-Xian Bai, Jing-Wang Bi, Li-Wen Ma, Jian Lei, Qing Yang, Hao Yu
Publikováno v: Chinese Journal of Cancer, Vol 36, Iss 1, Pp 1-9 (2017)
Abstract Background Metastatic colorectal cancer (mCRC) patients with progressive disease after all available standard therapies need new medication for further treatment. Famitinib is a small-molecule multikinase inhibitor, with promising anticancer
Externí odkaz: https://doaj.org/article/60f8fa644b284514af46dc26b0515928
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Third‐generation EGFR inhibitor HS‐10296 in combination with famitinib, a multi‐targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR‐mutant non‐small cell lung cancer cells
Autor: Zhang, Mi, Quan, Haitian, Fu, Li, Li, Yun, Fu, Haoyu, Lou, Liguang
Publikováno v: Thoracic Cancer, Vol 12, Iss 8, Pp 1210-1218 (2021)
Thoracic Cancer
Background As a highly heterogeneous disease, lung cancer has a multitude of cellular components and patterns of gene expression which are not dependent on a single mutation or signaling pathway. Thus, using combined drugs to treat lung cancer may be
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6535bce05adabb9974aa495b07aeefa9
https://doaj.org/article/55267ec3411d49fbbf76ee812de82b63
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje